<div id="readability-page-1"><p><span>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)</span> had its target price lifted by research analysts at HC Wainwright  from $30.00 to $32.00 in a research report issued on Monday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 321.33% from the company's previous close.</p><p>Several other research analysts have also recently commented on BCRX. Evercore ISI  reiterated an &#34;in-line&#34; rating and issued a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Needham &amp; Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, November 4th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 15th. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, December 2nd. Finally, Citizens Jmp decreased their target price on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one  has given a Sell rating to the company. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.50.</p><p><b>Get Our Latest Stock Report on BioCryst Pharmaceuticals</b></p><h2>BioCryst Pharmaceuticals Stock Performance</h2><p>Shares of BCRX stock traded up $0.03 during mid-day trading on Monday, hitting $7.60. 1,874,402 shares of the stock traded hands, compared to its average volume of 4,014,464. The company's 50-day simple moving average is $7.15 and its 200-day simple moving average is $8.22. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -152.06 and a beta of 0.91. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31. </p><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same quarter last year, the firm posted ($0.07) earnings per share. BioCryst Pharmaceuticals's revenue was up 36.1% compared to the same quarter last year.  Analysts forecast that  BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In related news, insider Alane P. Barnes sold 19,770 shares of the company's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.65, for a total value of $151,240.50. Following the completion of the sale, the insider owned 345,476 shares in the company, valued at approximately $2,642,891.40. This represents a 5.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 161,680 shares of company stock worth $1,164,401. 5.10% of the stock is currently owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. raised its stake in shares of  BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company's stock worth $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter.  Arrowstreet Capital Limited Partnership raised its holdings in  BioCryst Pharmaceuticals by 2,103.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after acquiring an additional 4,084,403 shares in the last quarter.  Assenagon Asset Management S.A. boosted its position in shares of  BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock worth $32,441,000 after acquiring an additional 3,606,566 shares in the last quarter.  Millennium Management LLC boosted its stake in  BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after buying an additional 3,022,769 shares in the last quarter.  Finally, Qube Research &amp; Technologies Ltd grew its holdings in shares of  BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock valued at $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Institutional investors own  85.88% of the company's stock. </p><h2>About BioCryst Pharmaceuticals</h2> (Get Free Report)<p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than BioCryst Pharmaceuticals</li><li>Investing In Automotive Stocks</li><li>Super Micro's Sell-Off Is a Mirage—Here’s Why the Rally May Come Back Fast</li><li>Canada Bond Market Holiday: How to Invest and Trade </li><li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BCRX

<p>HC Wainwright raised BioCryst Pharmaceuticals' target price from $30 to $32, maintaining a "buy" rating, suggesting a potential upside of 321.33%. Other analysts have varied ratings, with an average "Moderate Buy" consensus and a $19.50 target. BioCryst's stock performance shows a slight increase, with insider and institutional activity noted. The company reported a revenue increase of 36.1% year-over-year, despite missing EPS estimates.</p>

HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock